ral activity was detected with any of the tested compounds. The combination antiviral efficacy of three-drug combinations involving the calanolides, and the efficacy of two-and three-drug combinations using a (+)-calanolide A-resistant challenge virus (bearing the T139I amino acid change in the reverse transcriptase), was also evaluated in vitro. These assays suggest that the best combination of agents based on in vitro anti-HIV assay results would include the calanolides in combination with lamivudine and nelfinavir, since this was the only three-drug combination exhibiting a significant level of synergy. Combination assays with the (+)-calanolide A-resistant strain yielded identical results as seen with the wild-type virus, although the concentration of the calanolides had to be increased.
Evidence demonstrating the superiority of combination, rather than monotherapeutic, anti-HIV strategies has rapidly accumulated in clinical trials (Stuart et al., 1998) . To date, the use of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) in monotherapeutic strategies has been less than optimal. The primary problems experienced in these treated patients include drug toxicity and the appearance of drug-resistant viruses. In most cases, the presence of pre-existing populations of virus that are resistant to a single drug can be documented (Strair et al., 1993) . Drug resistance has become a critical issue in HIV chemotherapy since it has been shown that the rate of transmission of drug resistant strains of virus may be as high as 10% in the USA and Europe (Yerly et al., 1999; Salomon et al., 2000; Boden et al., 1999) . However, the preexistence of virus strains that are resistant to all therapeutic components of anti-HIV drug cocktails has not been demonstrated, and these strains are presumably unlikely to exist prior to therapy. Thus, a consensus has developed over the past several years regarding the treatment of patients with multiple drugs, and combination therapy is now the standard for care in HIV-infected individuals. Combination therapy offers the benefits of targetting multiple steps in the virus replication cycle, reducing the concentration of single agents to levels that will not yield toxicity, and will significantly reduce virus load in patients. In most cases, these combination therapies have resulted in the reduction of plasma virus load in infected individuals to undetectable levels for prolonged periods of time. Decrease in virus load has been directly correlated with enhanced prognosis and decreased rates of disease progression (Mellors et al., 1996 (Mellors et al., , 1997 . These cocktail therapies appear to be efficacious at reducing virus load in the blood, as well as in other tissue reservoirs (Stuart et al., 1998) . The NNRTI, (+)-calanolide A, and its congeners, costatolide and dihydrocostatolide (Figure 1 ), inhibit the reverse transcriptase (RT) of HIV and have been determined to be efficacious in preclinical assays against HIV-1, both in vitro and in vivo (Currens et al., 1996a; Buckheit et al., 1999; Flavin et al., 1996; Kashman et al., 1992; Xu et al., 1999) . The inhibitory activity of the calanolides, like other NNRTIs, is highly specific for HIV-1 RT, with no documented activity against the RT of HIV-2, SIV or avian myeloblastosis virus (AMV), or against either cellular RNA polymerase or cellular DNA polymerases (Currens et al., 1996b; Berger et al., 1989; Pengsuparp et al., 1996) . The calanolides exhibit a complex interaction with the p66 domain of RT and may bind at two distinct sites on the RT (Currens et al., 1996b; Buckheit et al., 1999; Arnold et al., 1996) . We have recently reported the activity of the calanolides in cell culture assays when tested against a variety of clinical virus strains and drug-resistant isolates Quan et al., 1999) . One highly unique feature of the calanolide class of HIV-1 inhibitors is their ability to inhibit viruses possessing the NNRTI-specific Y181C mutation in the RT. We have also evaluated the selection of drug-resistant strains in cell culture when infected cells were treated with combinations of agents, including the calanolides .
In this report, we continue and extend our evaluations with the calanolides to examine their potential when used in combination with a variety of other anti-HIV compounds, representing different mechanisms of anti-HIV action. Two-and three-drug combination assays, using both wild-type and calanolide-resistant virus challenge strains, were performed. The calanolides might be best used in combination with specific NRTIs and PIs, and suggest that the clinical evaluation of calanolide combinations is warranted.
Materials and Methods

Materials
The compounds (+)-calanolide A, costatolide, dihydrocostatolide and (+)-12-oxo(+)-calanolide A were obtained either synthetically or from natural sources (Kashman et al., 1992; Flavin et al., 1996; Xu et al., 2000) . Additional antiviral agents used in the combination assays were obtained commercially [zidovudine (ZDV), lamivudine (3TC), zalcitabine (ddC) and didanosine (ddI)), from the National Cancer Institute [nevirapine (NVP), resobene and UC10] or from Dr John Driscoll [indinavir (IDV), saquinavir (SQV ), ritonavir (RTV ) and nelfinavir (NFV)]. Crystalline stock materials were stored at -70°C and solubilized in 100% dimethylsulphoxide (DMSO). All stocks were diluted at least 400-fold prior to performing drug susceptibility assays. Materials required for the performance of reverse transcriptase inhibition assays, anti-HIV assays and for the growth and maintenance of established and fresh human cells have been previously described (Buckheit et al., 1994b) . The MacSynergy II program was obtained from Dr Mark Prichard and Dr Charles Shipman at the University of Michigan (Ann Arbor, Mich., USA).
Anti-HIV assays
Evaluation of the antiviral activity of test compounds was performed in CEM-SS cells as previously described (Buckheit et al., 1994b) . Antiviral and toxicity data are reported as the concentration of drug required to inhibit 50% of virus-induced cell killing or virus production (EC 50 ), and the concentration of drug required to reduce cell 
Combination antiviral analysis
Analysis of drug combination assays was performed as previously described (Buckheit et al., 1994a) , utilizing the anti-HIV assay method as described above, with statistical evaluations performed according to the method of Prichard and Shipman (1990) . For each combination assay, five concentrations (twofold dilutions from the high test concentration) of calanolide were evaluated in all possible combinations with seven concentrations of a second anti-HIV agent. In three-drug combination assays, the same protocol was used with the following change. Two of the test compounds were combined and treated as a single compound (with a known antiviral interaction) and were diluted together in equimolar ratios as described above. This compound mixture was then tested in all possible combinations with seven concentrations of the third test compound.
The results of the combination assays are presented three-dimensionally at each combination concentration, yielding a surface of activity extending above (synergy) or below (antagonism) the plane of additivity. The volume of the surface is calculated and expressed as a synergy volume (µM 2 %) calculated at the 95% confidence interval (Prichard & Shipman, 1990) . For these studies, synergy is defined as drug combinations yielding synergy volumes greater than 50 µM 2 %. Slightly synergistic activity and highly synergistic activity have been defined as yielding synergy volumes of 50-100 µM 2 % and >100 µM 2 %, respectively. Synergy volumes between 0-50 µM 2 % are considered additive. Negative synergy volumes are considered antagonistic. Volumes between 0 and -50 µM 2 % are still considered additive, while values between -50 and -100 µM 2 %, and volumes less than -100 µM 2 %, are considered slightly and highly antagonistic, respectively. The results obtained from the two-drug assays measure the antiviral interaction of the two compounds in the anti-HIV assays. The results obtained from the three-drug assays measure the effect of the addition of the third compound on the antiviral activity of the two-compound mixture.
Results and Discussion
The activity of the NNRTIs, (+)-calanolide A, costatolide, dihydrocostatolide and (+)-12-oxo(+)-calanolide A, were examined in combination with a variety of anti-HIV drugs using the standard XTT assay and data evaluation by the three-dimensional model of Prichard and Shipman (Buckheit et al., 1994a) . We examined the activity of the calanolides when used in combination with other known active anti-HIV agents with the goal of using these in vitro data to prioritize the testing of the calanolides in combination in human clinical trials. The Prichard and Shipman MacSynergy II program compares the experimentally realized percent protection at each point in a checkerboard of drug concentrations with the expected level of activity of the combination, based on the activity of the compounds †Within the concentration ranges used, no evidence of synergistic toxicity was detected in any of these combination anti-HIV assays. Table 2 . Effect of calanolides in combination with inhibitors of HIV-1 replication* alone. Subtraction of the expected activity from the realized activity results in a positive value (synergy), negative value (antagonism) or zero (additivity). These synergy values were plotted to form a three-dimensional synergy plot. A combination of drugs yielding an additive interaction results in a planar surface, a synergistic interaction results in a three-dimensional surface extending above the plane, and an antagonistic interaction results in a three-dimensional surface extending below the plane. The volume of the three-dimensional surface that is formed was calculated, resulting in a synergy volume value that quantifies and defines the interaction of the two compounds. Definition of the interaction of the compounds is based on the synergy volume as described in the Materials and Methods section.
In our combination anti-HIV assays, the combination of ZDV plus ddC was used as a control for synergistic antiviral activity, ddI plus ribavirin was used as a control for antagonistic antiviral activity, and ZDV plus an attachment inhibitor (the sulphonated dye resobene) was used as a control for additive antiviral activity. The confirmatory results obtained with these three combination assays are presented in Table 1 .
The results presented in Table 2 indicate that the combination of the calanolides with a variety of mechanically diverse HIV inhibitory compounds yielded either additive or synergistic interactions. It should be noted that the var- ious anti-HIV agents used in combination with the calanolides are all active against (+)-calanolide A-resistant virus and the calanolide compounds are all active against virus strains that are resistant to these second anti-HIV agents . Thus, the use of these agents in combination should yield an effective therapeutic strategy in which strains resistant to one compound in the combination remain fully sensitive to the second antiviral agent. Antagonistic anti-HIV activity or synergistic toxicity to the host cells was not observed for any of the combinations evaluated herein. When used in combination with the calanolides, NRTIs and PIs yielded synergistic anti-HIV activity. Both additive and synergistic antiviral interactions were observed when the calanolides were combined with other NNRTIs. These results are consistent with previous in vitro studies with a variety of NNRTIs that demonstrated significant synergy when nucleoside inhibitors are combined with NNRTIs (Buckheit et al., , 1993a (Buckheit et al., ,b, 1995 Yang et al., 1995) . The greatest levels of synergy were detected when the calanolides were used in combination with the nucleoside analogues ZDV and 3TC (Figures 2 and 3) , the PIs NFV, SQV and RTV and the NNRTI thiocarboxanilide ( Figure  4) . With synergy volumes greater than 100 µM 2 %, each of these combinations is considered to be highly synergistic. Interestingly, representative examples of additive interactions of the calanolides with certain compounds in each of these classes were also found. Specifically, (+)-calanolide A plus ddC, (+)-calanolide A plus indinavir, and (+)-calanolide A plus nevirapine were determined to exhibit additive interactions. The data presented in Table 2 also indicate that costatolide routinely yields greater levels of synergy when used in combination with other anti-HIV agents, as compared to the same combinations including (+)-calanolide A, whereas dihydrocostatolide exhibits little, if any, synergistic interactions with these same agents. Significant differences in results were obtained when the calanolides were tested in combination with the nucleoside ddC, where costatolide exhibited a extremely high synergy volume (525 µM 2 %). These data also indicate that the use of the calanolides with the NNRTI thiocarboxanilide (UC-781) resulted in significant synergy, which was surprising since combinations of NNRTIs routinely yield additive interactions. In fact, combination of the calanolides with nevirapine and the thiocarboxanilide analogue UC10 yielded only additive interactions. Furthermore, the addition of thiocarboxanilide lead to synergistic interactions with all three tested calanolide congeners, including dihydrocostatolide, which exhibited additive interactions with all other tested compounds except ZDV. The synergistic effect of calanolides plus thiocarboxanilide may result from the compounds interacting at different sites on the RT, or having multiple antiviral targets. It is known that the calanolides bind at sites outside of the NNRTI hydrophobic binding site, and UC-781 is known to bind tightly to the RT, resulting in virus inactivation (Currens et al., 1996b; Buckheit et al., 1999; Arnold et al., 1996; Barnard et al., 1997; Balzarini et al., 1998) .
In order to further explore the efficacy of the (+)-calanolide analogues as a component of a drug cocktail, we adapted the Prichard and Shipman MacSynergy II program to evaluate the effects of three-drug combinations. These assays were performed by adding two of the compounds together at defined molar ratios and treating this mixture as a single compound. As a result, we were able to evaluate the effect of the addition of the third compound on the twodrug mixture. In many cases, the initial mixture of two drugs (calanolide plus a NRTI, such as ZDV) yielded a synergistic interaction when evaluated as a two-drug combination. In the three-drug assays, however, this synergistic interaction is already accounted for in the final results and is not a factor in the interpretation of the three-drug combination data. Thus, based on our understanding of how the two-drug mixture affected HIV replication, the activity of the third compound was superimposed over this baseline interaction, yielding a synergy volume resulting only from the addition of the third compound. For example, in most cases, the calanolides used in combination with a NRTI yielded a synergistic interaction. When a third NRTI was added to the synergistic combination of the two compounds, the result was additive, indicating that the addition of the third compound did not increase the level of synergy exhibited between the calanolides and the initial NRTI. As seen in Table 3 , we evaluated a variety of threedrug combinations. In each of these assays, (+)-calanolide A was tested in the three-drug combination assay with a mixed compound of either ZDV or 3TC, plus a variety of other active anti-HIV agents. In nearly every case the addition of (+)-calanolide A to the compound mixture only added to the interaction. However, a synergistic interaction was detected when (+)-calanolide A was added to the mixture of NFV and 3TC ( Figure 5 ) and a slightly synergistic interaction was found when (+)-calanolide A was added to the mixture of SQV and 3TC. These in vitro assays would support the trends being followed in the clinic with the combination of both NRTIs and PIs, and suggest that addition of a NNRTI may also be beneficial.
Combination anti-HIV assays were also used to determine the effect of the use of a (+)-calanolide-resistant challenge strain of virus on the efficacy of two-and three-drug cocktails (Table 4) . Wild-type IIIB virus and the (+)-calanolide A-resistant strain possessing a T139I amino acid change in the RT were used in these assays. Combinations of the calanolides with NVP, NVP plus ZDV, and NFV plus ZDV, were evaluated with both strains of challenge virus. In each of the assays the concentrations of the calanolide analogues was increased in the assays employing the resistant strain. Similar results were obtained in the two-and three-drug combination assays, irrespective of the strain of virus used. These data suggest that the combination of calanolide compounds with one NRTI and one PI generally yielded synergistic anti-HIV activity, while the combination of the calanolides with one NRTI and one NNRTI was additive.
These results suggest that combination anti-HIV therapy may be clinically promising if in vitro test results are predictive of results obtained in patients. As (+)-calanolide A clinical trials proceed, the future utility of convergent and divergent combination therapies using RT inhibitors and PIs in combination with (+)-calanolide A, or one of its congeners, warrants further clinical consideration.
